Stock Track | Sage Therapeutics Stock Plunges After Halting Zuranolone MDD Program, ZULRESSO Discontinuation

Stock Track

Oct 30, 2024

Shares of Sage Therapeutics Inc. (NASDAQ: SAGE) plummeted 5.78% in after-hours trading on Monday, October 29, 2024, following the company's third-quarter 2024 financial results and pipeline updates.

The biopharmaceutical company reported a narrower net loss of $93.6 million for the quarter, compared to a net loss of $201.6 million in the same period last year. However, the market reacted negatively to Sage's decision to halt further development of its investigational drug zuranolone as a treatment for major depressive disorder (MDD) in the U.S.

Sage and its partner Biogen had previously received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application for zuranolone in MDD. The companies concluded that the significant additional investment and time required for further studies made the MDD program commercially unviable in the U.S. market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1122663107"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1122663107\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1122663107?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-30 05:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122663107","market":"hk","top_or_hot":-1,"title":"Stock Track | Sage Therapeutics Stock Plunges After Halting Zuranolone MDD Program, ZULRESSO Discontinuation","media":"Stock Track","content":"<p>Shares of Sage Therapeutics Inc. (NASDAQ: SAGE) plummeted 5.78% in after-hours trading on Monday, October 29, 2024, following the company's third-quarter 2024 financial results and pipeline updates.</p>\n\n<p>The biopharmaceutical company reported a narrower net loss of $93.6 million for the quarter, compared to a net loss of $201.6 million in the same period last year. However, the market reacted negatively to Sage's decision to halt further development of its investigational drug zuranolone as a treatment for major depressive disorder (MDD) in the U.S.</p>\n\n<p>Sage and its partner Biogen had previously received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application for zuranolone in MDD. The companies concluded that the significant additional investment and time required for further studies made the MDD program commercially unviable in the U.S. market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Sage Therapeutics Stock Plunges After Halting Zuranolone MDD Program, ZULRESSO Discontinuation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Sage Therapeutics Stock Plunges After Halting Zuranolone MDD Program, ZULRESSO Discontinuation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-10-30 05:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Sage Therapeutics Inc. (NASDAQ: SAGE) plummeted 5.78% in after-hours trading on Monday, October 29, 2024, following the company's third-quarter 2024 financial results and pipeline updates.</p>\n\n<p>The biopharmaceutical company reported a narrower net loss of $93.6 million for the quarter, compared to a net loss of $201.6 million in the same period last year. However, the market reacted negatively to Sage's decision to halt further development of its investigational drug zuranolone as a treatment for major depressive disorder (MDD) in the U.S.</p>\n\n<p>Sage and its partner Biogen had previously received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application for zuranolone in MDD. The companies concluded that the significant additional investment and time required for further studies made the MDD program commercially unviable in the U.S. market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SAGE","symbol_name":"Sage Therapeutics","start_time":0,"source_url":"","article_id":"1122663107","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122663107","pubTimestamp":1730236622,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Sage Therapeutics Inc.  plummeted 5.78% in after-hours trading on Monday, October 29, 2024, following the company's third-quarter 2024 financial results and pipeline updates.The biopharmaceutical company reported a narrower net loss of $93.6 million for the quarter, compared to a net loss of $201.6 million in the same period last year. However, the market reacted negatively to Sage's decision to halt further development of its investigational drug zuranolone as a treatment for major de","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SAGE":"Sage Therapeutics"},"translate_title":"股票追踪Sage Therapeutics股价在停止Zuranolone MDD计划、ZULRESSO停产后暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SAGE":1},"content_text":"Shares of Sage Therapeutics Inc. (NASDAQ: SAGE) plummeted 5.78% in after-hours trading on Monday, October 29, 2024, following the company's third-quarter 2024 financial results and pipeline updates.\nThe biopharmaceutical company reported a narrower net loss of $93.6 million for the quarter, compared to a net loss of $201.6 million in the same period last year. However, the market reacted negatively to Sage's decision to halt further development of its investigational drug zuranolone as a treatment for major depressive disorder (MDD) in the U.S.\nSage and its partner Biogen had previously received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application for zuranolone in MDD. The companies concluded that the significant additional investment and time required for further studies made the MDD program commercially unviable in the U.S. market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}